Pivotal-Point Follow-Up Disc Medicine (IRON): Specialist in Rare Blood Disorders Delivers Strong Study Results on Bitopertin
Reading Time: 1 minute
Disc Medicine develops novel therapies for rare, severe hematological disorders. The biotech company focuses on the regulation of hemoglobin and iron metabolism to assist patients with hereditary blood formation disorders. The stock surged on October 19 following outstanding Phase 2 results from the APOLLO study for the lead candidate Bitopertin in erythropoietic protoporphyria. The data showed a significant reduction in toxic protoporphyrin IX and a dramatic improvement in patients' light tolerance. With the positive APOLLO data, Disc Medicine...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
